Verekitug clinical trials
Also written UPB-101.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses verekitug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Upstream Bio Inc. (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test verekitug.
- Sep 2027A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)Phase 2 · Upstream Bio Inc.
- Oct 2027A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDPhase 2 · Upstream Bio Inc.
Studies
Open first, then newest update. How each study uses verekitug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 2Upstream Bio Inc.NCT06164704Written as Verekitug (UPB-101)
- A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDActive, not recruitingPhase 2Upstream Bio Inc.NCT06981078Written as Verekitug
- A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)Active, not recruitingPhase 2Upstream Bio Inc.NCT06966479Written as Verekitug
- A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)CompletedPhase 2Upstream Bio Inc.NCT06196879Written as Verekitug (UPB-101)
- Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in AsthmaticsCompletedPhase 1Upstream Bio Inc.NCT05448651Written as UPB-101
- Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian AdultsCompletedPhase 1Upstream Bio Inc.NCT05653479Written as UPB-101
Codes
What other systems call verekitug · ClinicalTrials.gg INT017957
- UNII (FDA) T1NAO7YDA7VEREKITUGOne source FDA
- NCI Thesaurus C203156VerekitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T1NAO7YDA7 | VEREKITUG | One source FDA |
| NCI Thesaurus | C203156 | Verekitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.